Interview with Christina Gerde
Read about the interview
“My story shows just how critical early detection can be. I’m still here today largely because I trusted my own sense that something wasn’t right, even when the healthcare system assured me everything looked fine. Looking back, the cancer could have been detected much earlier with an effective blood test. I was already reporting small symptoms nearly two years before my diagnosis. Despite undergoing numerous examinations, nothing was found. Had a reliable blood test been available at that time, my pancreatic tumour might have been identified in stage 1 or 2, rather than stage 3a. That difference matters. Earlier detection could have spared me from becoming a high-risk patient, facing a 75% chance of relapse even after surgery and chemotherapy. And in pancreatic cancer, a relapse is often a death sentence. This is why early detection tools like those pursued in the SHIELD project are so vital.